| Name | Title | Contact Details |
|---|
The NCH Healthcare System is a not-for-profit multi-facility healthcare system located in Naples, Florida. The system includes two hospitals (NCH Healthcare System – Downtown Naples Hospital and NCH Healthcare System – North Naples Hospital) with a total of 681 beds collaborating with 630 physicians to care for more than 32,000 patients each year. Outpatient facilities include Walk-in Centers, Wellness Centers, Rehabilitation Centers, Wound Care Facilities, and Infusion Centers in Naples, North Naples, Marco Island, Bonita Springs, and Estero. NCH`s Emergency Departments and outpatient facilities had over 120,000 visits for the past two years. Caring for all ages in the communities it serves, NCH performs almost 500 open heart surgeries and 3,400 newborn deliveries each year.
Carolina Centers for Medical Excellence is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HNI Healthcare designs intelligent processes and technology to empower talented people to transform healthcare.
Plexus Learning Designs is a Marblehead, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic